Primary aggressive CD8+ cutaneous T-cell lymphoma (CTCL) is a rare, rapidly progressive peripheral cutaneous malignant condition. The rapid progression is accompanied by a dismal prognosis, despite attempts to treat with multiple treatment regiments. Herein, we report a case of primary aggressive CD8+ CTCL that successfully responded to pralatrexate.
Accepted for Publication: September 14, 2013.Corresponding Author: Francisco A. Kerdel, MD, Florida Academic Dermatology Centers, The University of Miami Hospital, 1400 NW 12th Ave, Ste 4, Miami, FL 33136 (email@example.com).
Published Online: January 22, 2014. doi:10.1001/jamadermatol.2013.8647.
Conflict of Interest Disclosures: Dr Kerdel received honoraria from Amgen, Abbott, and Janssen and received grants from Amgen, Abbott, Pfizer, Eli Lilly, Celgene, Stiefel, and Novartis.
Additional Contributions: We are indebted to Carlos H. Nousari, MD, Sadegh Amini, MD, and Carlos A. Vidal, MD, who were also involved in the care of this patient.